Novartis AG (NOVN) Given Average Rating of “Hold” by Brokerages
Shares of Novartis AG (VTX:NOVN) have received an average recommendation of “Hold” from the fifteen analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is CHF 85.
A number of research firms have weighed in on NOVN. HSBC Holdings plc set a CHF 85 target price on Novartis AG and gave the company a “buy” rating in a report on Wednesday, June 21st. Berenberg Bank set a CHF 85 target price on Novartis AG and gave the company a “neutral” rating in a report on Friday, July 14th. JPMorgan Chase & Co. set a CHF 75 target price on Novartis AG and gave the company a “neutral” rating in a report on Wednesday, July 19th. Deutsche Bank AG set a CHF 81 target price on Novartis AG and gave the company a “neutral” rating in a report on Wednesday, July 19th. Finally, Goldman Sachs Group, Inc. (The) set a CHF 80 target price on Novartis AG and gave the company a “neutral” rating in a report on Friday, July 14th.
Novartis AG (NOVN) opened at 82.90 on Friday. Novartis AG has a 12-month low of CHK 67.40 and a 12-month high of CHK 84.35. The firm has a market capitalization of CHK 194.23 billion and a P/E ratio of 30.27. The firm has a 50 day moving average of CHK 81.20 and a 200 day moving average of CHK 78.64.
COPYRIGHT VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/01/novartis-ag-novn-given-average-rating-of-hold-by-brokerages.html.
Novartis AG Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.